Latest / Community Health Media
Dr. Mark Pegram & Dr. Seth Wander - Endocrine Resistance & ESR1 Mutations
How should clinicians approach endocrine resistance in ER-positive metastatic breast cancer?
Dr. Mark Pegram and Dr. Seth Wander explore the evolving science of endocrine resistance, ESR1 mutations, liquid biopsy testing, and precision oncology in hormone receptor-positive, HER2-negative metastatic breast cancer. Drawing from decades of research and clinical experience, they discuss how resistance develops, why repeat molecular testing matters, and how emerging therapies are reshaping treatment strategies.
The conversation covers:
Mechanisms of endocrine resistance in metastatic breast cancer…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.